Candel Therapeutics Targets Q4 2026 BLA for Prostate Cancer Drug, Initiates Pivotal NSCLC Phase 3, Secures Funding
Summary
Candel Therapeutics announced its fourth quarter and full year 2025 financial results alongside significant corporate highlights. The company is advancing its lead candidate, aglatimagene, towards a planned BLA submission for prostate cancer in Q4 2026 and is preparing to initiate a pivotal Phase 3 clinical trial in non-small cell lung cancer (NSCLC) in Q2 2026. Additionally, Candel received FDA clearance for its linoserpaturev IND in recurrent high-grade glioma. These clinical milestones are supported by recent strategic financing, including a term loan, a follow-on equity offering, and a royalty financing agreement, which significantly strengthens the company's balance sheet. This comprehensive update provides a clear and aggressive clinical development roadmap with multiple material catalysts throughout 2026, substantially de-risking the company's operational runway and future prospects. Investors should monitor the upcoming Q2 2026 Phase 3 prostate cancer data and the initiation of the NSCLC pivotal trial.
At the time of this announcement, CADL was trading at $5.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $373.6M. The 52-week trading range was $4.25 to $9.08. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.